AVADEL PHARMACEUTICALS (AVDL) Stock Fundamental Analysis
NASDAQ:AVDL - IE00BDGMC594 - Common Stock
14.8 USD
-0.07 (-0.47%)
Taking everything into account, AVDL scores 5 out of 10 in our fundamental rating. AVDL was compared to 193 industry peers in the Pharmaceuticals industry. AVDL is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. AVDL is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
AVDL had negative earnings in the past year.
In the past year AVDL had a positive cash flow from operations.
In the past 5 years AVDL reported 4 times negative net income.
AVDL had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
AVDL's Return On Assets of -1.56% is fine compared to the rest of the industry. AVDL outperforms 77.20% of its industry peers.
Looking at the Return On Equity, with a value of -3.22%, AVDL is in the better half of the industry, outperforming 78.76% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 1.37%, AVDL is in the better half of the industry, outperforming 78.24% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.56% | ||
| ROE | -3.22% | ||
| ROIC | 1.37% |
ROA(3y)-76.86%
ROA(5y)-51.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Operating Margin value of 1.02%, AVDL is doing good in the industry, outperforming 77.72% of the companies in the same industry.
With an excellent Gross Margin value of 89.64%, AVDL belongs to the best of the industry, outperforming 93.78% of the companies in the same industry.
In the last couple of years the Gross Margin of AVDL has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.02% | ||
| PM (TTM) | N/A | ||
| GM | 89.64% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.73%
2. Health
2.1 Basic Checks
AVDL has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for AVDL has been increased compared to 1 year ago.
AVDL has more shares outstanding than it did 5 years ago.
AVDL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 4.35 indicates that AVDL is not in any danger for bankruptcy at the moment.
AVDL has a better Altman-Z score (4.35) than 77.72% of its industry peers.
There is no outstanding debt for AVDL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.35 |
ROIC/WACC0.18
WACC7.49%
2.3 Liquidity
AVDL has a Current Ratio of 2.79. This indicates that AVDL is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of AVDL (2.79) is comparable to the rest of the industry.
AVDL has a Quick Ratio of 2.38. This indicates that AVDL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.38, AVDL is in line with its industry, outperforming 48.70% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.79 | ||
| Quick Ratio | 2.38 |
3. Growth
3.1 Past
AVDL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 97.37%, which is quite impressive.
AVDL shows a strong growth in Revenue. In the last year, the Revenue has grown by 132.35%.
Measured over the past years, AVDL shows a very strong growth in Revenue. The Revenue has been growing by 23.35% on average per year.
EPS 1Y (TTM)97.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%171.43%
Revenue 1Y (TTM)132.35%
Revenue growth 3YN/A
Revenue growth 5Y23.35%
Sales Q2Q%64.15%
3.2 Future
The Earnings Per Share is expected to grow by 46.24% on average over the next years. This is a very strong growth
Based on estimates for the next years, AVDL will show a very strong growth in Revenue. The Revenue will grow by 23.79% on average per year.
EPS Next Y146.52%
EPS Next 2Y88.55%
EPS Next 3Y61.75%
EPS Next 5Y46.24%
Revenue Next Year60.93%
Revenue Next 2Y44.59%
Revenue Next 3Y34.03%
Revenue Next 5Y23.79%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AVDL. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 18.30, the valuation of AVDL can be described as rather expensive.
76.68% of the companies in the same industry are more expensive than AVDL, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.80, AVDL is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 18.3 |
4.2 Price Multiples
75.13% of the companies in the same industry are more expensive than AVDL, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of AVDL indicates a somewhat cheap valuation: AVDL is cheaper than 75.13% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 254.52 | ||
| EV/EBITDA | 213.01 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
AVDL's earnings are expected to grow with 61.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y88.55%
EPS Next 3Y61.75%
5. Dividend
5.1 Amount
No dividends for AVDL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:AVDL (8/28/2025, 2:42:17 PM)
14.8
-0.07 (-0.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners83.09%
Inst Owner Change4.07%
Ins Owners4.83%
Ins Owner Change2.42%
Market Cap1.34B
Analysts84.29
Price Target19.51 (31.82%)
Short Float %12.59%
Short Ratio7.69
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)144.64%
Min EPS beat(2)31.2%
Max EPS beat(2)258.07%
EPS beat(4)3
Avg EPS beat(4)78.96%
Min EPS beat(4)-20.15%
Max EPS beat(4)258.07%
EPS beat(8)4
Avg EPS beat(8)33.56%
EPS beat(12)4
Avg EPS beat(12)3.14%
EPS beat(16)6
Avg EPS beat(16)-5.8%
Revenue beat(2)2
Avg Revenue beat(2)5.07%
Min Revenue beat(2)1.52%
Max Revenue beat(2)8.61%
Revenue beat(4)3
Avg Revenue beat(4)2.45%
Min Revenue beat(4)-1.22%
Max Revenue beat(4)8.61%
Revenue beat(8)7
Avg Revenue beat(8)7.62%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)11.68%
PT rev (3m)9.29%
EPS NQ rev (1m)-26.57%
EPS NQ rev (3m)62.25%
EPS NY rev (1m)5.73%
EPS NY rev (3m)56.35%
Revenue NQ rev (1m)4.25%
Revenue NQ rev (3m)10.97%
Revenue NY rev (1m)4.41%
Revenue NY rev (3m)5.59%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 18.3 | ||
| P/S | 6.06 | ||
| P/FCF | 254.52 | ||
| P/OCF | 246.06 | ||
| P/B | 14.78 | ||
| P/tB | 18.15 | ||
| EV/EBITDA | 213.01 |
EPS(TTM)-0.03
EYN/A
EPS(NY)0.81
Fwd EY5.46%
FCF(TTM)0.06
FCFY0.39%
OCF(TTM)0.06
OCFY0.41%
SpS2.44
BVpS1
TBVpS0.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.56% | ||
| ROE | -3.22% | ||
| ROCE | 1.74% | ||
| ROIC | 1.37% | ||
| ROICexc | 3.68% | ||
| ROICexgc | 5.63% | ||
| OM | 1.02% | ||
| PM (TTM) | N/A | ||
| GM | 89.64% | ||
| FCFM | 2.38% |
ROA(3y)-76.86%
ROA(5y)-51.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.73%
F-Score5
Asset Turnover1.18
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 0.24 | ||
| Cash Conversion | 93.05% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.79 | ||
| Quick Ratio | 2.38 | ||
| Altman-Z | 4.35 |
F-Score5
WACC7.49%
ROIC/WACC0.18
Cap/Depr(3y)15.99%
Cap/Depr(5y)11.39%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)97.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%171.43%
EPS Next Y146.52%
EPS Next 2Y88.55%
EPS Next 3Y61.75%
EPS Next 5Y46.24%
Revenue 1Y (TTM)132.35%
Revenue growth 3YN/A
Revenue growth 5Y23.35%
Sales Q2Q%64.15%
Revenue Next Year60.93%
Revenue Next 2Y44.59%
Revenue Next 3Y34.03%
Revenue Next 5Y23.79%
EBIT growth 1Y102.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year186.69%
EBIT Next 3Y90.38%
EBIT Next 5Y44.74%
FCF growth 1Y106.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y106.45%
OCF growth 3YN/A
OCF growth 5YN/A